Fig. 6.

ND2158 delays CLL progression in the TCL1 adoptive transfer mouse model. a Treatment schedule of ND2158 in TCL1 AT model. BID twice a day, i.p. intraperitoneally. b Left panel: Absolute tumor cell count (CD19⁺CD5⁺) in peripheral blood (PB) over time as analyzed by flow cytometry. Right panel: Spleen weight of vehicle- (n = 7) and ND2158-treated (n = 7) mice. Representative examples of spleens are shown. c Left panel: Tumor load (CD19⁺CD5⁺ cells out of CD45⁺ cells) in spleen (SP), peritoneal cavity (PC), lymph nodes (LN), and bone marrow (BM) as acquired by flow cytometry. Right panel: Median fluorescence intensity (MFI) of PD-L1 in CLL cells from PC and LN. Horizontal bars represent population means. Mann−Whitney test was used for statistical analysis. *P < 0.05, **P < 0.01